[18F]FDG PET/CT对危重患者感染性和炎症性病灶的诊断价值:系统评价与荟萃分析
该系统评价与诊断准确性荟萃分析纳入8项研究共228例危重患者,其中7项研究181例进入荟萃分析,评估[18F]FDG PET/CT检测感染性和炎症性病灶的价值。汇总灵敏度91%(95%CI 80–96)、特异度78%(95%CI 64–87),DOR 35(95%CI 10–121),LR+ 4(95%CI 2.3–7.1),LR− 0.12(95%CI 0.05–0.28),未检出显著统计异质性或发表偏倚。作者认为其是可靠的检测工具,对临床决策有显著影响,尤其指导介入操作和优化药物治疗,但需前瞻性研究进一步验证。
要点
- 汇总灵敏度91%、特异度78%,支持[18F]FDG PET/CT检测危重患者感染和炎症灶。
- 多数研究显示其影响患者管理,主要是指导介入操作及调整抗菌或糖皮质激素治疗。
- 除一项研究外,多数研究未报告与患者转运或PET/CT扫描相关的不良事件。
核心结论
- [18F]FDG PET/CT似乎是检测危重患者感染性和炎症性病灶的可靠影像工具。
- 其检查结果对临床决策有显著影响,尤其指导介入操作和优化药物治疗。
- 仍需前瞻性研究在无偏倚环境和稳健参考标准下确定发现率,以进一步验证其诊断价值。
研究设计与样本
- 系统评价与诊断准确性荟萃分析,检索PubMed/MEDLINE、Embase和Cochrane Library截至2025年5月发表的研究。
- 系统评价纳入8项研究共228例患者,其中7项研究181例患者符合荟萃分析条件。
- 计算汇总灵敏度、特异度、阳性与阴性似然比及诊断比值比及其95%CI,并评估发表偏倚和统计异质性。
主要发现
- 检测危重患者感染性和炎症性病灶的汇总灵敏度为91%(95%CI 80–96)、特异度为78%(95%CI 64–87)。
- 汇总诊断比值比为35(95%CI 10–121),阳性似然比为4(95%CI 2.3–7.1),阴性似然比为0.12(95%CI 0.05–0.28)。
- 未检出显著统计异质性或发表偏倚。
- 多数研究未报告与患者转运或PET/CT扫描相关的不良事件,仅一项研究例外。
关键数值与推荐
- 汇总灵敏度91%(95%CI 80–96)、特异度78%(95%CI 64–87)、DOR 35(95%CI 10–121)。
- 汇总LR+为4(95%CI 2.3–7.1),LR−为0.12(95%CI 0.05–0.28)。
临床怎么用
- [18F]FDG PET/CT可用于危重患者感染性和炎症性病灶的检测,其结果有助于指导介入操作和调整抗菌或糖皮质激素等药物治疗。
局限性
- 作者指出需前瞻性研究在无偏倚环境和稳健参考标准下确定发现率,以进一步强化和验证其诊断价值。
- 多数研究未报告与患者转运或PET/CT扫描相关的不良事件,仅一项研究例外。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 2-deoxy-2-[18F]-fluoro-D-glucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) is a hybrid imaging tool increasingly recognized for its effectiveness in evaluating inflammatory and infectious diseases. An emerging application of [18F]FDG PET/CT is the detection of infectious and inflammatory foci in critically ill patients within the intensive care unit (ICU). We performed a systematic review and a diagnostic accuracy meta-analysis to assess the value of [18F]FDG PET/CT in this setting. METHODS: A comprehensive literature search was conducted across PubMed/MEDLINE, Embase, and the Cochrane Library databases, covering studies published up to May 2025. Pooled estimates of sensitivity, specificity, positive and negative likelihood ratios (LR + and LR-), and diagnostic odds ratios (DOR) along with their 95% confidence intervals (95% CI), were calculated. In addition, assessment of publication bias and statistical heterogeneity was conducted. RESULTS: Eight studies (n = 228 patients) were included in the systematic review with seven studies (n = 181 patients) eligible for the meta-analysis. Most contributions of [18F]FDG PET/CT to patient management involved guiding interventional procedures and adjustments to medical therapy such as antimicrobial and corticosteroid treatment. Adverse events related to patient transport or PET/CT scan were not reported in most studies, with exception of one. In terms of diagnostic performance for identifying infectious and inflammatory foci in critically ill patients, the pooled sensitivity, specificity, DOR, LR + and LR − were 91% (95%CI: 80–96), 78% (95%CI: 64–87), 35 (95%CI: 10–121), 4 (95%CI: 2.3–7.1) and 0.12 (0.05–0.28), respectively. No significant statistical heterogeneity or publication bias was detected. CONCLUSION: [18F]FDG PET/CT appears to be a reliable imaging tool for detecting infectious and inflammatory foci in critically ill patients. Its findings have a significant impact on clinical decision-making, particularly in guiding interventional procedures and optimizing medical therapy. However, prospective studies to determine the incidence of findings in a unbiased setting and with use of robust reference standards are warranted to further strengthen and validate the diagnostic value of [18F]FDG PET/CT.
引用
- Treglia G, Albano D, Wittebole X, et al. Diagnostic value of [18F]FDG PET/CT for detection of infectious and inflammatory foci in critically ill patients: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2026. PMID: 41593360. doi:10.1007/s00259-025-07759-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。